Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT02905578Phase 2Completed
- Sponsor
- University of Iowa
- Start
- Nov 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ascorbic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by University of Iowa. Primary endpoint: Overall Survival. Started Nov 2018; status: completed.
02
Drugs
ascorbic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02905578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905578.